Novartis (NVS)
(Delayed Data from NYSE)
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Zacks.com featured highlights W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis
by Zacks Equity Research
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
Novo Nordisk (NVO) Announces Positive Obesity Program Data
by Zacks Equity Research
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Invest in These Dividend Growth Stocks Amid Default Fears
by Sweta Killa
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress
by Zacks Equity Research
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq
by Zacks Equity Research
Alimera's (ALIM) stock jumps 19.4% after the company inks a deal with Eyepoint to acquire additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now
by Zacks Equity Research
ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.
AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
by Zacks Equity Research
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study
by Zacks Equity Research
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
by Zacks Equity Research
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth
by Zacks Equity Research
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
by Zacks Equity Research
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
What Makes Novartis (NVS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Top Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
Here's Why Novartis (NVS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks.com featured highlights include PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger
by Zacks Equity Research
PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger are part of the Zacks Screen of the Week article.
5 Dividend Growth Stocks to Buy for Safe Returns
by Sweta Killa
PulteGroup (PHM), Novartis (NVS), Boyd Gaming (BYD), Cummins (CMI) and W.W. Grainger (GWW) could be solid choices for your portfolio.
Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.
Novartis (NVS) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform
by Zacks Equity Research
AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.